What are some of the current challenges in the management of advanced skin cancers, and what is coming next? In this short video, leading skin cancer expert Professor Michael Henderson talks about the emerging role of immune checkpoint inhibitor therapy for advanced non-melanoma skin cancers.
"We may start to see a significant change in the way we approach advanced basal and squamous cell carcinomas."
"We've reached a crossroads in the management of advanced basal cell and squamous cell carcinoma," says Prof Henderson in the video below.
"We have got reasonable agents in hedgehog inhibitors for basal cell cancer, but we know about a third of the patients who are responding stop treatment because of the side effects.
"So we need new agents and we need to do better. And one possibility is going to be the role of immune checkpoint inhibitor therapy. Treating people early, at a stage when their tumour burden is low, immune checkpoint inhibitors work better.
"We may start to see a significant change in the way we approach advanced basal cell cancer in squamous cell cancer."
Watch all this and much more in the full video here:
Interested in skin cancer medicine? Learn more with HealthCert's university-assured and CPD-accredited Professional Diploma program in Skin Cancer Medicine, delivered online or with optional workshops.
Engaging with this blog can help meet your annual
|
How to claim your CPD hours
|